Preclinical studies in patient-derived xenograft models of HER2-positive breast cancer brain metastases demonstrated that T-DXd markedly reduces tumor volume and extends survival, even in T-DM1-resistant cases [64]. Here, ERBB2 is linked to breast carcinoma.